• Argenica Therapeutics (AGN) receives approval to progress to the fourth and final cohort dosing of ARG-007 in its phase one trial
• Following an extensive review of data from the third cohort of participants, the company received notice from the safety review committee (SRC) that no clinically relevant abnormal results due to administration of the drug were recorded
• AGN says it will provide a final update on the phase one clinical trial at the completion of the final cohort safety data review in late December
• Argenica Therapeutics is down 4.04 per cent, trading at 47.5 cents just before market close

Argenica Therapeutics (AGN) has received approval to progress to the fourth and final cohort dosing of ARG-007 in its phase one trial.

Following an extensive review of data from its third cohort of participants, the company received notice from the safety review committee (SRC) that no clinically relevant abnormal results due to administration of the drug were observed.

The company has been working to develop novel therapeutics to reduce brain tissue death after strokes and other types of brain injury.

Of the eight participants dosed in the trial, only two participants noted non-serious adverse events, including a headache, nausea and symptomatic postural hypotension. However, as the study is currently blinded, it’s not known whether these participants received ARG-007 or a placebo.

“The completion of the third cohort and approval to move to our final cohort gives us great confidence in the safety and tolerability profile of ARG-007,” Argenica CEO and Managing Director Dr Liz Dallimore said.

“We will commence the final cohort dosing in the coming days with dosing of the whole cohort expected in mid-December.”

Argenica will provide a final update on the phase one clinical trial at the completion of the final cohort safety data review in late December.

Argenica Therapeutics was down 4.04 per cent, trading at 47.5 cents just before market close.